As proof of concept of the platform, Lamellar has taken two LAMELLASOME nucleic acid products and is advancing them through preclinical efficacy testing. These products target Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.(LAMELLASOME IPF-NA) for treatment of Idiopathic Pulmonary Fibrosis. (LAMELLASOME CF-NA) for treatment of Cystic Fibrosis. Both are Orphan Drug Designated conditions with high unmet clinical need.
LAMELLASOME products have an excellent safety profile as demonstrated in GLP non-clinical safety and toxicity testing, and in two clinical studies.
Lamellar is looking for opportunities to advance these products through out-licensing or joint development agreements.